Suresnes, September 6, 2023 – 6 p.m. CET – In accordance with the provisions of Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers:
|
Date |
Number of shares making up the capital |
Number of GROSS voting rights |
Number of NET voting rights |
08/31/2023 | 9,090,681 | 9,090,681 | 9,090,681 |
Furthermore, the company recalls that, since 1
er
January 2023, the number of shares issued each month by the company breaks down as follows:
|
Wording |
OCEANE |
ORA |
TOTAL |
|
Before consolidation | |||
January-23 | 348 132 988 | 0 | 348 132 988 |
February-23 | 295 370 368 | 0 | 295 370 368 |
March-23 | 931 876 528 | 0 | 931 876 528 |
April-23 | 4,388,888,222 | 0 | 4,388,888,222 |
May-23 | 0 | 0 | 0 |
|
After grouping | |||
Jun-23 | 622 278 | 0 | 622 278 |
July-23 | 813 514 | 155,909 | 969 423 |
Aug-23 | 5,648,423 | 1,074,666 | 6,723,089 |
As a reminder, the permanent monitoring of the creation of new shares resulting in particular from the conversions of OCEANEs and the exercises of BSA
E
is the subject of summary tables that are systematically updated and available on the NEOVACS website.
ABOUT NEOVACS
Neovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNα Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, the full results were presented on the 13
th
2019 international lupus congress. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment which would be more effective, well tolerated and very flexible in its administration.
For more information :
www.neovacs.fr
Jérôme FABREGUETTES-LEIB | Anne-Charlotte DUDICOURT |
[1]
Business combination on June 2, 2023 by means of an exchange of 8,000 old shares for 1 new share
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
nXBslcZrY5zJnp+aaJ2WnGaVb2aTxWadZ2nHyJKZlMmVa29mmGhlZ8mbZnFim2lm
– To check this key:
https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
– Information relating to the total number of voting rights and shares making up the capital
Full and original press release in PDF format:
https://www.actusnews.com/news/81640-nvcs_cp_ddv_aout_2023.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com